- Home
- ORI vs ROIV Comparison
ORI vs ROIV Comparison
Compare ORI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORI
- ROIV
- Stock Information
- Founded
- ORI 1923
- ROIV 2014
- Country
- ORI United States
- ROIV United Kingdom
- Employees
- ORI N/A
- ROIV N/A
- Industry
- ORI Property-Casualty Insurers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ORI Finance
- ROIV Health Care
- Exchange
- ORI Nasdaq
- ROIV Nasdaq
- Market Cap
- ORI 9.4B
- ROIV 7.8B
- IPO Year
- ORI N/A
- ROIV N/A
- Fundamental
- Price
- ORI $36.59
- ROIV $11.40
- Analyst Decision
- ORI Buy
- ROIV Buy
- Analyst Count
- ORI 1
- ROIV 4
- Target Price
- ORI $43.00
- ROIV $17.50
- AVG Volume (30 Days)
- ORI 1.6M
- ROIV 7.9M
- Earning Date
- ORI 07-24-2025
- ROIV 08-07-2025
- Dividend Yield
- ORI 3.17%
- ROIV N/A
- EPS Growth
- ORI 19.19
- ROIV N/A
- EPS
- ORI 3.04
- ROIV N/A
- Revenue
- ORI $8,329,500,000.00
- ROIV $29,053,000.00
- Revenue This Year
- ORI $8.35
- ROIV $3.28
- Revenue Next Year
- ORI $6.23
- ROIV $156.84
- P/E Ratio
- ORI $12.04
- ROIV N/A
- Revenue Growth
- ORI 10.83
- ROIV N/A
- 52 Week Low
- ORI $30.61
- ROIV $8.73
- 52 Week High
- ORI $39.84
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ORI 40.02
- ROIV 54.55
- Support Level
- ORI $36.19
- ROIV $10.71
- Resistance Level
- ORI $38.20
- ROIV $11.58
- Average True Range (ATR)
- ORI 0.67
- ROIV 0.29
- MACD
- ORI -0.12
- ROIV 0.00
- Stochastic Oscillator
- ORI 16.60
- ROIV 62.16
About ORI Old Republic International Corporation
Old Republic International Corp offers a diverse range of specialized insurance products to individuals and institutions. The company operates in two segments: Specialty Insurance and Title Insurance. The Insurances provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.